Forecasting the unforecastable
Most diagnostics founders start at a lab bench. Mohan Purushothaman started in a spreadsheet - the one that decides what a drug costs. His Ph.D. from Johns Hopkins was not in molecular biology but in pharmaceutical pricing, an unusually finance-adjacent credential for a man who now runs a blood-test company. That detail explains a lot about how Progentec Diagnostics thinks.
Today he is co-founder, chairman, and CEO of Progentec, a company headquartered in Oklahoma City with a deceptively simple ambition: stop treating autoimmune disease only after it erupts, and start predicting it. The lead program, built in collaboration with the Oklahoma Medical Research Foundation, focuses on lupus - a disease defined by its unpredictability, where patients live between calm stretches and sudden flares with little warning. Progentec's platform, aiSLE DX, is designed to read proprietary blood biomarkers and flag a coming flare weeks in advance.
It is a strange thing to build a business around: the absence of an event. A test that earns its keep by telling you something bad is on the way, while there is still time to act. For a founder who spent his early career calculating the value of a drug across its entire life cycle, the logic is familiar - value lives in timing, not just in the molecule.
The route that was not a straight line
Before Oklahoma, before lupus, there was Roche. Purushothaman spent roughly five years inside the Swiss pharmaceutical giant, leading the formulation of life-cycle pricing strategies across a large portfolio of products. Pricing is one of those quiet functions that decides whether a breakthrough reaches patients or stalls in a reimbursement queue. He learned the economics of medicine from the inside - which drugs win, which lose, and why the math so often has nothing to do with the science.
Then he built something. His practice at Net Margins grew into a serious operation and was eventually acquired by Alliance Life Sciences, where he served as Global Practice Lead for Pricing and Market Access until 2014. Along the way he designed an Enterprise Price Optimization software that became a leading tool used by a number of major pharmaceutical companies. He had, in effect, productized his own expertise - turning a consulting craft into software that scaled without him in the room.
That is the through-line. Roche taught him the value of a drug. Net Margins and Alliance taught him how to package judgment into a product. Both lessons show up in Progentec, where the bet is that a diagnostic plus a digital layer can do for patients what pricing software did for pharma teams: replace guesswork with a signal you can act on.
2014: the pivot to lupus
In 2014, the year he left the pricing world, Purushothaman co-founded Progentec. The choice of disease was not random. Lupus is a market the rest of the industry finds frustrating - heterogeneous, hard to diagnose, harder to monitor, and devastating when a flare hits unannounced. It is exactly the kind of problem where a better early signal could change a patient's year. Partnering with the Oklahoma Medical Research Foundation gave the young company a research engine; the OMRF connection remains central to its credibility.
Progentec's pitch crystallized into two products. The aiSLE DX Flare Prediction Test reads blood biomarkers to anticipate flares before symptoms surface. A companion aiSLE DX classification test aims to sharpen the diagnosis itself, which in lupus can take years and many false starts. Around the tests, the company built LupusCorner, a patient-engagement community and a vehicle for fully remote clinical studies - the digital monitoring half of the founder's stated vision.
How the bet works
The money, and who believed
In January 2020, Progentec announced a $5 million Series A led by Plains Venture Partners. The cap table reads like a quiet vote of confidence from institutions that rarely chase hype: Stanford University, Mayo Clinic, the Oklahoma Medical Research Foundation, OCA Ventures out of Chicago, NMC Health from Abu Dhabi, the Oklahoma Seed Capital Fund, and Oklahoma Angel Capital Fund II among them. For a company in Oklahoma City - not a coastal biotech hub - assembling that mix of academic medical centers and venture money was its own kind of validation.
The raise was framed not as a finish line but as fuel for the vision Purushothaman has repeated in nearly the same words for years: biomarkers with high sensitivity and specificity, fused with continuous remote monitoring, aimed at millions of patients. It is a founder who knows his one sentence and says it consistently - a discipline that comes more naturally to someone trained in market positioning than in pipetting.
What makes him unusual
The interesting thing about Purushothaman is not that he runs a diagnostics company. It is the angle of approach. He thinks like an economist who happens to operate in biology. Where many founders fall in love with the assay, he seems most animated by the system around it - reimbursement, access, the path from a lab result to a clinical decision to a patient who actually benefits. He was a Research Fellow at Harvard before Hopkins, so the academic instinct is there. But the commercial instinct is what he built a career on, and it shapes the company's center of gravity.
That dual fluency is rare. Plenty of scientists can explain a biomarker. Plenty of executives can explain a market. Purushothaman is comfortable in the same sentence with both, which is why Progentec frames itself less as a test and more as a "comprehensive solution" - the language of someone who spent years thinking about how value moves through a healthcare system, not just how a molecule behaves in a tube.
For now, the company remains a focused, early-stage operation - small headcount, big surface area, one disease it is determined to understand better than anyone. The aspiration is plain: make autoimmune disease something that can be anticipated rather than merely endured. Whether the science fully delivers is a question still being written. But the founder's logic has been consistent from the first pitch - the value is in the warning, and the warning is worth building a company around.